A research team led by assistant professor Min-Ho Seo of Busan, South Korea’s Pusan National University have developed a soft, bioresorbable, implantable device to relieve neuropathic pain by cooling peripheral nerves.
Taiwan's Food and Drug Administration has approved Brain Navi Biotechnology Co. Ltd.’s Naotrac, an autonomous neurosurgical navigation robot that uses artificial intelligence (AI) to map out the most precise surgical pathway for minimal tissue damage to the brain.
For the one in eight couples struggling to conceive, the improvements in infertility treatments achieved by employment of artificial intelligence (AI) in diagnostics, personalized therapies and embryo selection may soon mean the difference between childlessness and the family of their dreams.
Communication between adipose tissue and the brain increases the risk of cognitive impairment in patients with insulin resistance through extracellular vesicles (EVs) containing microRNAs (miRNAs). Neurons could be damaged when these nucleotides reach the hippocampus guided by membrane proteins in prediabetic overweight people.
Australia’s Therapeutic Goods Administration (TGA) is proposing that devices be subject to good clinical practices (GCP) inspections, and it is proposing two approaches to achieve that goal.
Shanghai Microport Ep Medtech Co. Ltd. went public on the Shanghai Stock Exchange STAR Market and raised ¥1.17 billion (US$169.5 million) with its initial public offering. The company’s issue price was ¥16.51 per share. After opening at ¥15.50 per share, the share price dived to ¥13.15 at the closing of its first trading day. Microport Ep is an associated company of the Hong Kong-listed Microport Scientific Corp.
Sichuan Jinjiang Electronic Science and Technology Co. Ltd. (JJET) recently completed series A+ and series B rounds, raising a total of ¥700 million (US$101 million) in series A and series B financing.
Women with endometriosis may soon be able to take a simple blood test to determine if they have the condition thanks to a new test being developed by Proteomics International Pty Ltd. that detects up to 78% of women with endometriosis.
Cell Envision Ltd. completed an angel round that will help expand its presence in the U.S. and Europe. Taiwan-based Cell Envision has developed a self-assembled cell arrangement (SACA) monitoring system that can improve patient survival rates of cancer, together with enhancements in reproductive medicine.
Founded in 2014, Bertis Co. Ltd. is developing proteomics-based diagnostics and biomarkers by combining artificial intelligence/machine learning (AI/ML) algorithms with high-performance mass spectrometry technology. Using this technology, it is able to quantify extremely small amounts of protein.
RSS
